Navigation Links
Thyroid hormones reduce damage and improve heart function after myocardial infarction in rats
Date:2/28/2013

Thyroid hormone treatment administered to rats at the time of a heart attack (myocardial infarction) led to significant reduction in the loss of heart muscle cells and improvement in heart function, according to a study published by a team of researchers led by A. Martin Gerdes and Yue-Feng Chen from New York Institute of Technology College of Osteopathic Medicine.

The findings, published in the Journal of Translational Medicine, have bolstered the researchers' contention that thyroid hormones may help reduce heart damage in humans with cardiac diseases.

"I am extremely excited about the prospects of improving heart disease outcomes in patients by restoring normal thyroid function in the heart," says Gerdes, professor and chair of biomedical sciences at New York Institute of Technology College of Osteopathic Medicine. "Since thyroid hormones are inexpensive, significant health care savings could also result."

In the study, funded by the National Institutes of Health's National Heart, Lung, and Blood Institute and the American Heart Association, scientists treated rats with thyroid hormones after myocardial infarction and examined changes at the cellular level. After eight weeks of treatment, researchers saw significant improvements in heart function and a reduction in the loss of cardiac myocytes, the cells responsible for the heart's pumping ability.

"Reducing the loss of cardiac myocytes is a major therapeutic target after a heart attack since this should lead to improved patient survival and reduced disability," Gerdes said.

Gerdes, who has conducted heart failure research for 35 years, has focused on the two major forms of thyroid hormones known as T3 and T4. Previous animal studies have shown that myocardial infarction leads to reduced cardiac levels of T3, a change that animal studies have demonstrated can eventually cause heart failure by itself. However, blood hormone levels may not always reflect this cardiac tissue deficiency. Although tissue T3 levels have not yet been measured in human hearts, available evidence suggests the same hormone loss likely occurs after myocardial infarction.

"This study clearly demonstrates dramatic benefits in a rat model of myocardial infarction. The challenge now is to determine if humans benefit similarly," says Gerdes.

Gerdes noted that many physicians are opposed to treating heart patients with thyroid hormones, largely due to the potential of increased arrhythmias from overdosing.

"We need to conduct more research to determine which form, T3 or T4, works best in humans and how to administer and monitor hormone treatment in a manner that restores cardiac T3 without increasing serum hormones to above normal levels," he said. "We are encouraged because all animal models of heart disease studied to this point have produced beneficial results as long as non-toxic doses are used. More recently, we have also developed a treatment approach in rats that restores cardiac tissue T3 while maintaining blood hormone levels within the normal range. This is an approach that should also work in humans. So, I believe we are now better prepared for clinical trials."


'/>"/>

Contact: Elaine Iandoli
eiandoli@nyit.edu
516-686-4013
New York Institute of Technology
Source:Eurekalert

Related medicine news :

1. HypothyroidMom.com Reveals Research Linking Hypothyroidism to the Deadliest Diseases of Our Time
2. Terris co-edits first textbook on thyroid surgery complications
3. HypothyroidMom.com Launches Thyroid Advocacy Site for Moms with Hypothyroidism
4. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
5. Overactive Thyroid May Raise Risk for Common Irregular Heartbeat
6. BPA shown to disrupt thyroid function in pregnant animals and offspring
7. Vandetanib in thyroid cancer: No proof of added benefit
8. First comprehensive guidelines for managing anaplastic thyroid cancer published in Thyroid journal
9. Mild Hyperthyroidism Wont Raise Heart Risk: Study
10. Poorer Patients Find Thyroid Cancer at Later Stage: Study
11. Mild increases in thyroid-stimulating hormone not harmful in the elderly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... issue of world hunger, and shares the simple and achievable answer. “The Land of ... member of the Fairview Missionary Church in Angola, Indiana where he works with the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... The drug delivery technology market is projected ... 1,179.20 billion in 2016, at a CAGR of 7.2% ... diseases, increasing demand for biologics, technological advancements, and new ... this market. Whereas, self-administration & home care and rising ... opportunities for players operating in this market. On the ...
Breaking Medicine Technology: